Microbix Biosystms J (TSE:MBX)
TSX:MBX
Top Page
Microbix Biosystms
(TSX:MBX)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.25
▲(15.45% Upside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.
Positive Factors
Balance Sheet Strength
Moderate leverage and a meaningful equity cushion reduce financial risk and give the company runway to fund operations, R&D and commercialization efforts. A healthier balance sheet supports flexibility for manufacturing investment, contractual production commitments and opportunistic buybacks without immediate refinancing pressure.
Negative Factors
Negative Cash Generation
Sustained negative operating and free cash flow signals cash burn that erodes liquidity and constrains reinvestment. Even with a cash balance, ongoing negative cash generation raises the likelihood of needing external funding, delaying margin recovery initiatives and limiting ability to finance scale‑up without dilutive or costly financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Moderate leverage and a meaningful equity cushion reduce financial risk and give the company runway to fund operations, R&D and commercialization efforts. A healthier balance sheet supports flexibility for manufacturing investment, contractual production commitments and opportunistic buybacks without immediate refinancing pressure.
Read all positive factors
Microbix Biosystms (MBX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$31.17M
Dividend YieldN/A
Average Volume (3M)57.61K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue Growth-26.81%
EPS Growth-161.24%
CountryCA
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding138,553,380
10 Day Avg. Volume59,614
30 Day Avg. Volume57,610
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.33
Price to Sales (P/S)1.98
P/FCF Ratio-42.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.50Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Microbix Biosystms Business Overview & Revenue Model
Company Description
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biol...
How the Company Makes Money
Microbix makes money primarily by selling specialized biological products and materials used by diagnostic test manufacturers, clinical laboratories, and other life science customers. Its key revenue streams include: (1) Quality assessment/externa...
Microbix Biosystms Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Neutral
The call mixes clear operational and strategic progress (sequential revenue growth, QAPs expansion, recombinant antigen commercialization, new client wins including the College of American Pathologists, improved cash collection, active share repurchases, and favorable Kinlytic FDA interactions) with material near-term financial challenges (a ~30% year-over-year revenue decline driven by a 49% drop in antigen sales due to China distributor inactivity, depressed gross margins from lower volumes, a Q1 net loss of $1.2M, and quarter-end receivable timing issues). Management framed the setbacks as tactical and emphasized diversification and efficiency gains to reduce volatility and restore margins as volumes scale.Positive Updates
Sequential Revenue Growth
Q1 fiscal 2026 revenue of $4.2M, up 13% sequentially from the prior quarter and reported as in line with budget expectations.
Negative Updates
Significant Year-over-Year Revenue Decline
Revenues declined ~30% year-over-year, driven predominantly by the absence of sales through the Chinese distributor (a revenue differential of over $2M vs prior periods).
Read all updates
Q1-2026 Updates
Positive
Negative
Sequential Revenue Growth
Q1 fiscal 2026 revenue of $4.2M, up 13% sequentially from the prior quarter and reported as in line with budget expectations.
Read all positive updates
Company Guidance
Management guided that breakeven is expected once quarterly revenues exceed in excess of $5.5M (management targets roughly $5.5–$6.0M per quarter) and that they are modeling full‑year fiscal 2026 revenues about 30% above the 2025 trough (roughly $18–$19M); Q1 actuals were $4.2M (up 13% sequentially, down ~30% YoY) with a controlled net loss of $1.2M, QAPs revenue of $1.9M (up 15% YoY) and antigen sales down 49% YoY largely due to a >$2M shortfall from the China distributor, gross margins compressed but should improve as revenues scale, operating expenses were at/below expectations (Q1 seasonally lower but expected to rise in Q2/Q3), accounts receivable more than doubled at quarter end (management collected $3.3M in January), cash was $10.6M at end‑January (up $1.5M from December), inventory held steady, allowance for doubtful accounts ~$35k, NCIB repurchases totaled ~700k shares (~$175k) in Q1 and ~1M shares to date with a current buyback pace of 15,000 shares/day (maximum daily allowance 20,339; ~3.75M/year at 15k/day), Kinlytic sBLA timing is targeted in late 2027, and recombinant antigen commercialization (first product: SARS‑CoV‑2 capsid) is now driving supply‑chain security and margin improvement.Microbix Biosystms Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.76M | 18.59M | 25.39M | 16.51M | 19.08M | 18.59M |
| Gross Profit | 7.83M | 9.85M | 15.39M | 7.48M | 11.12M | 11.04M |
| EBITDA | -1.59M | 428.23K | 6.21M | 1.96M | 3.73M | 5.66M |
| Net Income | -4.27M | -2.25M | 3.52M | -39.48K | 1.79M | 1.63M |
Balance Sheet | ||||||
| Total Assets | 36.59M | 37.41M | 38.10M | 35.65M | 33.15M | 28.83M |
| Cash, Cash Equivalents and Short-Term Investments | 9.10M | 12.11M | 12.96M | 11.61M | 13.49M | 9.99M |
| Total Debt | 8.11M | 6.77M | 6.40M | 6.65M | 5.82M | 7.74M |
| Total Liabilities | 9.98M | 9.62M | 9.80M | 11.03M | 8.21M | 10.27M |
| Stockholders Equity | 26.61M | 27.79M | 28.30M | 24.62M | 24.94M | 18.56M |
Cash Flow | ||||||
| Free Cash Flow | -4.24M | -877.58K | 2.44M | -2.11M | 1.44M | 804.20K |
| Operating Cash Flow | -3.48M | -80.29K | 4.35M | -1.09M | 3.47M | 2.11M |
| Investing Cash Flow | -764.61K | -797.30K | -1.91M | -1.02M | -2.03M | -622.34K |
| Financing Cash Flow | 289.54K | 27.00K | -1.08M | 229.21K | 2.06M | 8.41M |
Microbix Biosystms Technical Analysis
Negative
0.22
Price Trends
0.23
Negative
0.24
Negative
0.25
Negative
Market Momentum
>-0.01
Positive
42.05
Neutral
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.23, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.05 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MBX.
Microbix Biosystms Peers Comparison
UnderperformOutperform
Sector (51)
TSE:MBX
Microbix Biosystms
0.23
-0.18
-45.12%
TSE:BCT
BriaCell Therapeutics
5.64
-49.26
-89.73%
TSE:RVX
Resverlogix
0.11
0.06
133.33%
TSE:GSD
Devonian Health Group
10.60
-0.20
-1.85%
TSE:DTC
Defence Therapeutics
0.52
-0.38
-42.22%
TSE:TTI
Thiogenesis Therapeutics Corp
0.49
-0.04
-7.55%
Microbix Biosystms Corporate Events
Business Operations and StrategyProduct-Related Announcements
Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug
Positive
Mar 10, 2026
Microbix Biosystems and its U.S. commercialization partner Sequel Pharma have advanced the redevelopment of Kinlytic urokinase, a biologic drug used to dissolve blood clots, by modernizing the manufacturing process for its active ingredient. The c...
Business Operations and StrategyExecutive/Board ChangesStock Buyback
Microbix Issues New Stock Options to Retain Senior Talent and Manage Dilution
Neutral
Feb 24, 2026
Microbix Biosystems has granted 2,600,000 stock options under its shareholder-approved stock option plan to incentivize and retain its board, executives, and senior managers. The options, exercisable at $0.23 per share after a three-year vesting p...
Business Operations and StrategyFinancial Disclosures
Microbix Q1 Revenue Rebounds Sequentially as China Antigen Sales Slide
Negative
Feb 12, 2026
Microbix Biosystems reported first-quarter fiscal 2026 revenue of $4.2 million, up 13% from the prior quarter but 30% below the same period last year, reflecting ongoing recovery after setbacks with two major clients in 2025. The quarter was marke...
Business Operations and StrategyFinancial Disclosures
Microbix Q1 Revenue Rebounds Sequentially but China Slump Drives Loss
Negative
Feb 12, 2026
Microbix reported first-quarter fiscal 2026 revenue of C$4.2 million, up 13% from the prior quarter but down 30% year over year, as a steep drop in antigen sales to its Chinese distributor outweighed growth in other antigen customers and a 15% inc...
Business Operations and Strategy
Microbix Wins College of American Pathologists as New QAP Client
Positive
Feb 10, 2026
Microbix Biosystems has secured the College of American Pathologists as a new client for its quality assessment products, which will be used in CAP’s global proficiency testing and external quality assessment programs for clinical laboratori...
Business Operations and StrategyFinancial Disclosures
Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12
Neutral
Feb 5, 2026
Microbix Biosystems Inc. will release its financial statements and management discussion and analysis for the first quarter of fiscal 2026, covering the period ended December 31, 2025, before markets open on February 12, 2026. On the same day at 1...
Business Operations and StrategyProduct-Related Announcements
Microbix Unveils FFPE-Simulated QC Platform to Standardize Molecular Pathology Testing
Positive
Feb 4, 2026
Microbix Biosystems is presenting new results from its novel Quality Assessment Products (QAPs™) platform for Molecular Pathology at the Labquality Days diagnostics conference in Helsinki, showcasing simulated formalin-fixed paraffin-embedde...
Financial DisclosuresRegulatory Filings and Compliance
Microbix Tightens EBITDA Disclosure After OSC Review
Neutral
Jan 9, 2026
Microbix Biosystems Inc., a Canadian life sciences manufacturer specializing in antigens, quality assessment products, and reference materials for the global diagnostics market, has operations spanning over 30 countries and also develops proprieta...
Business Operations and StrategyProduct-Related Announcements
Microbix Launches First Recombinant SARS-CoV-2 Antigen for QAPs and Test Makers
Positive
Jan 7, 2026
Microbix Biosystems has commercialized its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, for use in its QAPs quality assessment line and for sale at commercial scale to test manufacturers, marking the first market-ready o...
Business Operations and StrategyFinancial Disclosures
Microbix Swings to Loss as China Demand Softens and Key Programs Are Cancelled
Negative
Dec 18, 2025
Microbix reported a challenging fiscal 2025, with full-year revenue falling 27% to $18.6 million and the company swinging from net income of $3.5 million in the prior year to a net loss of $2.2 million. The downturn was driven by the absence of pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.